Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI2536 + Metformin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI2536 | BI 2536|BI-2536 | PLK1 Inhibitor 18 | BI2536 inhibits polo-like kinase 1 (PLK1), which disrupts mitosis and induces apoptosis in tumor cells (PMID: 30414309, PMID: 32486290). | |
Metformin | Glucophage | Apo-Metformin | mTOR Inhibitor 51 | Glucophage (metformin) inhibits part of the mitochondrial respiratory chain and may exert antineoplastic effects through inhibition of mTOR and is FDA approved for type 2 diabetes (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|